**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 68038

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Survival after curative pancreaticoduodenectomy for ampullary adenocarcinoma in a South American population: A retrospective cohort study**

Fernandez-Placencia RM *et al*. Pancreaticoduodenectomy for AAC

Ramiro Manuel Fernandez-Placencia, Paola Montenegro, Melvy Guerrero, Mariana Serrano, Emperatriz Ortega, Mercedes Bravo, Lourdes Huanca, Stéphane Bertani, Juan Manuel Trejo, Patricia Webb, Jenny Malca-Vasquez, Luis Taxa, Alberto Lachos-Davila, Juan Celis-Zapata, Carlos Luque-Vasquez, Eduardo Payet, Eloy Ruiz, Francisco Berrospi

**Ramiro Manuel Fernandez-Placencia, Juan Celis-Zapata, Eloy Ruiz, Francisco Berrospi,** Hepato-Pancreato-Biliary Section, Department of Abdominal Surgery, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru

**Paola Montenegro, Mariana Serrano, Emperatriz Ortega,** Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru

**Melvy Guerrero, Mercedes Bravo, Lourdes Huanca, Patricia Webb, Luis Taxa,** Department of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru

**Stéphane Bertani,** International Joint Laboratory of Molecular Anthopological Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru

**Stéphane Bertani,** Unite Pharmacochim & Pharmacol Dev, UMR152, F-31062 Toulouse, France

**Juan Manuel Trejo, Jenny Malca-Vasquez, Alberto Lachos-Davila,** Department of Radiation Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru

**Carlos Luque-Vasquez, Eduardo Payet,** Department of Abdominal Surgery, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru

**Author contributions:** Fernandez-Placencia RM was the guarantor and designer of the study and carried out data acquisition, statistical analysis and interpretation, and drafting of the initial manuscript; Montenegro P, Serrano M and Ortega E participated in the acquisition, analysis and interpretation of the data and contributed to the initial draft of the manuscript; Guerrero M and Bravo M participated in the pathological reevaluation and contributed intellectual content; Bertani S participated in the design, data analysis and drafting of the initial manuscript; Huanca L, Trejo JM, Webb P, Taxa L, Lachos-Davila A, Celis-Zapata J, Luque-Vasquez C, Payet E and Ruiz E participated in the data analysis and contributed to the critical review of the manuscript along with important intellectual content; Berrospi F mentored, designed and critically revised the article for relevant intellectual content.

**Corresponding author: Ramiro Manuel Fernandez-Placencia, MD, FACS. Surgical Oncologist,** Hepato-Pancreato-Biliary Section, Department of Abdominal Surgery, Instituto Nacional de Enfermedades Neoplasicas, 2520 E Angamos Ave. Office 216 Surquillo, Lima 15038, Peru. ramirofp02@gmail.com

**Received:** May 10, 2021

**Revised:** September 28, 2021

**Accepted: January 13, 2022**

**Published online:**

**Abstract**

BACKGROUND

Ampullary adenocarcinoma (AAC) is a rare neoplasm that accounts for only 0.2% of all gastrointestinal cancers. Its incidence rate is lower than 6 cases per million people. Different prognostic factors have been described for AAC and are associated with a wide range of survival rates. However, these studies have been exclusively conducted in patients originating from Asian, European, and North American countries.

AIM

To evaluate the histopathologic predictors of overall survival (OS) in South American patients with AAC treated with curative pancreaticoduodenectomy (PD).

METHODS

We analyzed retrospective data from 83 AAC patients who underwent curative (R0) PD at the National Cancer Institute of Peru between January 2010 and October 2020 to identify histopathologic predictors of OS.

RESULTS

Sixty-nine percent of patients had developed intestinal-type AAC (69%), 23% had pancreatobiliary-type AAC, and 8% had other subtypes. Forty-one percent of patients were classified as Stage I, according to the AJCC 8th Edition. Recurrence occurred primarily in the liver (*n* = 8), peritoneum (*n* = 4), and lung (*n* = 4). Statistical analyses indicated that T3 tumour stage [hazard ratio (HR) of 6.4, 95% confidence interval (CI) of 2.5-16.3, *P* < 0.001], lymph node metastasis (HR: 4.5, 95%CI: 1.8-11.3, *P* = 0.001), and pancreatobiliary type (HR: 2.7, 95%CI: 1.2-6.2, *P* = 0.025) were independent predictors of OS.

CONCLUSION

Extended tumour stage (T3), pancreatobiliary type, and positive lymph node metastasis represent independent predictors of a lower OS rate in South American AAC patients who underwent curative PD.

**Key Words:** Gastrointestinal neoplasms; Adenocarcinoma; Ampulla; Pancreaticoduodenectomy; Survival; South America

Fernandez-Placencia RM, Montenegro P, Guerrero M, Serrano M, Ortega E, Bravo M, Huanca L, Bertani S, Trejo JM, Webb P, Malca-Vasquez J, Taxa L, Lachos-Davila A, Celis-Zapata J, Luque-Vasquez C, Payet E, Ruiz E, Berrospi F. Survival after curative pancreaticoduodenectomy for ampullary adenocarcinoma in a South American population: A retrospective cohort study. *World J Gastrointest Surg* 2021; In press

**Core Tip:** The pancreatobiliary type of ampullary adenocarcinoma, lymph node metastasis and T3 tumour stage (AJCC 8th Ed) are risk factors for lower overall survival in a South American population.

**INTRODUCTION**

Ampullary adenocarcinoma (AAC) is a rare neoplasm that represents 0.2% of all gastrointestinal cancers[1,2]. AAC has better prognosis and resection rates than pancreatic ductal adenocarcinoma (PDAC)[3,4]. This may be partly explained by the early symptom of jaundice caused by its location in the ampulla of Vater[5,6]. Nevertheless, three different epithelia (duodenal, biliary, and pancreatic) are present in the ampullary region[7], and their derived malignancies display different clinical behaviours[8]. Kimura and colleagues classified AAC into two histologic subtypes: Pancreatobiliary (PB) and intestinal (INT)[9]. Other features, such as preoperative CA 19-9[7], imaging[10], molecular phenotype[11,12], genetic mutations[13-15], and the diagnosis and classification of AAC[16], have been correlated with overall survival (OS). Consequently, the anatomic paradigm has shifted towards the interaction between genetic and epigenetic factors that determine OS and relapse-free survival (RFS)[14,17]. This may explain the wide range of outcomes reported in different centres (5-year OS: 30%-70%)[2].

However, most of these studies have been conducted in European, Asian, and North American countries. To the best of our knowledge, only one study has evaluated the impact of the lymph node ratio in predicting OS among AAC patients in Latin America[18]. Therefore, we evaluated the histopathologic predictors in AAC patients who underwent curative pancreaticoduodenectomy (PD) at the National Cancer Institute of Peru.

**MATERIALS AND METHODS**

***Study design and patient selection***

We conducted a retrospective cohort study in patients diagnosed with AAC who underwent curative (R0) PD between January 2010 and October 2020 at our tertiary centre. We specifically analysed histopathologic factors that influenced the patients’ overall survival. Our institutional review board approved this study (Protocol Number 21-17), according to the Declaration of Helsinki[19].

***Histopathology***

Double reads in a blinded manner by pathologists specializing in hepatobiliary cancers were applied to ensure the diagnosis of AAC and classification into INT intestinal (INT)- and pancreatobiliary (PB)-type according toKimura *et al*[9,20].

Morphologically, INT-type tumours are reminiscent of colorectal adenocarcinoma, with solid nests, tall columnar cells, and elongated pseudostratified nuclei[21]. A significant proportion of INT-type is related to intestinal adenomas, which correlates with the adenoma-carcinoma sequence[22]. Conversely, PB-type adenocarcinomas are similar to extrahepatic bile duct and pancreatic duct adenocarcinomas. The glandular units have more pleomorphism than the intestinal type, with no evident nuclear pseudostratification, and they are separated by stroma[21]. Additionally, a mixed subtype has been described as having more than 25% of each INT and PB differentiation or with hybrid features, such as intestinal architecture with pancreatobiliary cytology[23,24]. Immunohistochemistry has led to a better classification of this mixed subtype; nevertheless, a standard definition has not been established[24,25]. In the present study, the following antibodies were used to determine the dominant type: MUC1 (#6151, BioSB, California, United States), MUC2 (#6158, BioSB, California, United States), CDX2 (MAD-000645QD-12, Vitro S.A., Spain), CK20 (MAD-0005105QD-12, Vitro S.A., Spain), and MUC5AC (MAD-000434QD-12, Vitro S.A., Spain). In cases of no definite conclusion, the tumour was classified as tubular into “other subtypes”.

Resection was classified as R0 when the 1-mm width of the surgical margin was free of neoplastic cells[26]. Tumour and nodal staging were categorized according to the AJCC 8th Edition.

***PD***

PD was considered the treatment of choice because it was demonstrated to be a more radical approach to achieve satisfactory lymph node clearance and tumour-free surgical margins[27]. Patients were eligible for surgery after a comprehensive evaluation. The clinical parameters included performance and nutritional status, anatomy, and tumour extension (evaluated with contrast-enhanced computed tomography scan or magnetic resonance imaging). CA19-9 Levels were monitored within one month before surgery. We also assessed the vascular structures of the mesenteric and celiac axes along the diameter of the pancreatic duct.

Our surgical approach has been described previously[28]. In brief, the procedure was carried out using level 2 mesopancreas resection[29], and the pancreatic stump was managed using Blumgart, duct-to-mucosa, or modified dunking (at the discretion of the surgeon). In all cases, two Blake drains were placed around the pancreaticojejunostomy. Prophylactic octreotide was not used. External stents were applied in patients with a high risk of postoperative pancreatic fistula[30].

***Adjuvant therapy***

Patients with adjuvant therapy (AT) were interpreted as those who received chemotherapy (two or more courses), radiotherapy (with or without a sensitizing chemotherapy drug), or a combination of both. The AT regimen was left at the discretion of treating physicians, according to the best evidence available and/or institutional protocol.

***Patient follow-up***

Follow-ups and patient check-ups were performed on postoperative days 15, 30, and 90. computed tomography (CT) scans and CA 19-9 tests were scheduled every 4 mo after the index procedure during the first year, every 6 mo during the second year, and annually from the third year onward. The National Database for Civil Status (RENIEC) was solicited to determine the fate of patients. OS (months) was monitored from the date of surgery to the date of death or last follow-up, and patients with no events were censored. Any event (recurrence or death) was recorded during the follow-up. The cut-off for the last follow-up was 60 mo.

***Statistical analysis***

Continuous variables were reported as medians (interquartile ranges), and categorical variables were reported as counts (percentages). For the univariate analysis, the log-rank test was used, and the histopathologically relevant variables were integrated into a Cox regression model. Statistical analyses were performed with an alpha significance level of 0.05 using IBM SPSS v.25 (IBM Corp., Armonk, NY, United States) and R software (R Foundation for Statistical Computing, Vienna, Austria).

**RESULTS**

***Study population***

From 2010 to 2020, 297 PDs were performed at the National Cancer Institute of Peru. Patients with R1/R2 resection, unavailable slides for revision, incomplete medical records, or synchronic neoplasms were excluded from the study. All patients included in the study underwent R0 resection. After a thorough revision of the medical files, 83 patients were included in the present study. Clinical, laboratory, and operative patient characteristics are presented in Table 1. The median age of the patient cohort was 59 years [interquartile range (IQR), 49-67], with a predominance of women (ratio = 1.3). The mean follow-up time was 39 mo. Twenty-five patients (30%) died during the follow-up period.

***Histopathologic characteristics***

Sixty-nine percent of patients had developed INT-type AAC (69%), 23% PB-type AAC, and 8% other subtypes (including five patients with the tubular subtype and two patients with the tubular subtype with signet ring cells). Approximately 40% of cases demonstrated pancreatic invasion (T3 tumour stage), and 40% of patients had lymph node metastasis. Thirty-four (41%), 20 (24%), and 29 (35%) patients had stage I, II, and III disease, respectively. The histopathological characteristics of the cohort are shown in Table 2.

***Use of AT***

Twenty-four patients received AT (15 patients underwent chemotherapy, two patients underwent radiotherapy, and seven patients were subjected to both treatments). The most frequently employed chemotherapy regimen included gemcitabine, which was administered to 20 patients (24%). When chemoradiotherapy was applied, a dose of 4500 cGy in 25 sessions was administered using capecitabine as a sensitizing agent.

The evaluation of AT on OS was impaired by the heterogeneity of the AT regimen and the number of patients. Therefore, we decided not to include the AT variable in the survival analysis.

***Patterns of recurrence***

Recurrent distant metastases were diagnosed during the postoperative period in the liver (*n* = 12), peritoneum (*n* = 8), and lung (*n* = 7). Additionally, lymph node recurrences around the superior mesenteric artery and the retroperitoneal space were primarily observed in one and two patients, respectively (Table 3).

***Overall survival and prognostic factors***

The 5-year OS rate in the cohort was 62% (Figure 1A). Applying the Cox regression model, three predictive factors were identified, *i.e.*, T staging, lymph node metastasis, and PB type. Time and outliers had no impact on these independent factors, according to the modelling (Supplementary Figures) (Table 4).

***Impact of the T tumour classification***

Univariate analysis showed lower OS in patients with T3 classification (*P* < 0.001). The 5-year OS rates were 80% in T1/T2 patients and 30% in T3 patients, with a median OS of 30% in the latter group. According to the multivariate analysis, T3 patients had an HR of 6.4 (95%CI: 2.5-16.3, *P* < 0.001) (Figure 1B).

***Effect of lymph node invasion***

Patients with lymph node metastases (N+) had a lower survival rate than those with no lymph node invasion (N0) (*P* = 0.001). The 5-year OS rates in the N+ and N0 groups were 38% and 80%, respectively. The median OS was 46 mo in the N+ group. The HR was 4.5 (95%CI: 1.8-11.3, *P* = 0.001) (Figure 1C).

***Influence of the histopathologic subtype***

PB-type patients had a lower OS than patients with INT or other subtypes (*P* = 0.004). The 5-year OS rate for PB-type patients was 38%, whereas patients with INT or other subtypes had a 5-year OS rate of 70%. The median OS was 46 mo in PB-type patients, whereas the OS in the intestinal/other group was not reached during the follow-up period. The HR was 2.7 (95%CI: 1.2-6.2, *P* = 0.025) in PB-type patients (Figure 1D).

**DISCUSSION**

To the best of our knowledge, the present study represents the first retrospective histopathologic work on AAC performed in a tertiary centre in South America, in which PD and the multimodal approach are standard. Our findings indicate that T3 tumour classification (pancreatic invasion), positive lymph node metastasis, and PB type are independent prognostic factors of OS in AAC patients treated with PD (R0).

Various factors have previously been described to be associated with AAC patient outcomes. In a meta-analysis, Zhou and colleagues identified age (> 65 years old), tumour size (> 20 mm), poor differentiation, PB-type, pT3-T4 stage diseases, lymph node metastasis, perineural invasion, lymphovascular invasion, pancreatic invasion, and positive surgical margins as independent factors associated with lower survival[32]. However, Koprowski and colleagues claimed that histotypes were not correlated with OS and concluded that disease stage was the primary determinant of patient outcomes[33]. In this study, the authors report 32% locoregional recurrence, despite the median number of retrieved lymph nodes and the low number of patients with R1 resection. Moreover, Quero and collaborators recently corroborated this finding about no difference between INT- and PB-types, but higher overall and recurrence-free survivals with excision of the mesopancreas[34].

Since AT allocation is based on tumour and nodal stages, we decided to consider these variables in the Cox model. We further stratified the patient cohort according to histopathologic subtypes (*i.e.*, INT, PB, and "others"). Of note, we did not observe the mixed subtype in our cohort from South America, contrasting with the studies published in other regions of the world[16,31].

Our model supports the predictive impact of the histology of AAC on survival in a patient cohort from South America. In our hands, PB type, pT3 stage, and lymph node metastases were associated with lower OS; other variables scrutinized were not significantly associated with OS. The low rate of locoregional recurrence reported in our cohort could be partly explained by the application of level 2 mesopancreas resection, in accordance with the data by Quero and collaborators[34].

AAC has been documented to have a better prognosis than PDAC. However, the present study suggests that there are detrimental factors associated with subgroups of AAC patients, with OS rates comparable to PDAC (Figure 2). In this regard, our data suggest that a better outcome would be primarily explained by the biology of the tumour and secondarily by its location. Hence, assessing the impact of AT in high-risk patients is of utmost relevance. In the ESPAC-3 study, which included 428 patients with periampullary adenocarcinoma, the use of chemotherapy (5-fluorouracil/leucovorin or gemcitabine) demonstrated a benefit in OS (HR 0.75) but no greater effectiveness based on the histological type[35]. Additionally, a multicentre retrospective analysis did not report any benefit of adjuvant chemotherapy in AAC patients, including those with high-risk criteria (N+ or advanced stages T3 and T4)[36]. Other studies have provided more contrasting results on the impact of adjuvant chemotherapy on OS[31,37-39]. Regarding adjuvant radiotherapy, benefits have essentially been analysed among PDAC patients, preventing definite conclusions in AAC patients[40-42]. A recent meta-analysis showed that AT, especially chemoradiotherapy, was associated with increased OS among patients with PB-type or high-risk factors[43].

There is a lack of specific guidelines for AAC, except one that comprises the management of biliary tract and ampullary carcinomas[44]. The authors recommend AT in patients with high-risk features (pancreatic invasion, lymph node metastasis, and perineural invasion) but did not specify any regimen. The predictive ability of mutation driver mutations (*e.g.*, TP53, KRAS, and ELF3) in AAC histotypes has not been studied in great detail[45]. The characterization of AAC patient subgroups, based on their molecular alterations, would provide information on the choice of AT after radical surgery.

There are some limitations to recognize in the present study. Our primary AAC patient population displayed a high perioperative mortality rate (10 patients were excluded from this study), which we addressed and analysed previously[28]. We consider this a very important drawback, in addition to the retrospective design of the study. Another weakness was the heterogeneity in the multimodal management of the patients, which is reflected in international practices[31,39,46]. Therefore, we decided not to evaluate the impact of AT, as few patients would have been included in each group. Accordingly, further prospective studies are required because of the limited evidence available to date.

**CONCLUSION**

PB type, T3 tumour stage, and positive lymph node metastasis are independent predictors of lower survival in South American patients with ampullary adenocarcinoma treated by curative pancreaticoduodenectomy. Further evaluation of adjuvant and multimodal treatments is warranted, especially in patients with these high-risk factors.

**ARTICLE HIGHLIGHTS**

***Research background***

Ampullary adenocarcinoma (AAC) is a rare neoplasm that has not been studied previously in South American countries.

***Research motivation***

AAC might have different patterns of recurrence and overall survival than what has been reported in centres from Europe, Asia or North America.

***Research objectives***

To identify risk factors and their impact on overall survival in patients who underwent pancreaticoduodenectomy (PD) for AAC.

***Research methods***

We conducted a retrospective cohort study and analysed histopathologic predictors of survival in a Cox regression model.

***Research results***

Nearly two-thirds of patients had the intestinal-type AAC and around 25% had the Pancreatobiliary (PB)-type AAC. However, overall survival (OS) was lower for the latter subtype. Independently of the T3 and N+ tumour stage.

***Research conclusions***

Patients with PB-type AAC, T3 and N+ tumour stage are at higher risk of lower survival after curative PD.

***Research perspectives***

Identification of high-risk patients would guide the clinicians for the use of AT. Further studies are warranted.

**ACKNOWLEDGEMENTS**

We would like to thank Pr. Lorenzo-Bermejo J for his valuable support in the review of the statistical methods

**REFERENCES**

1 **Askew J**, Connor S. Review of the investigation and surgical management of resectable ampullary adenocarcinoma. *HPB (Oxford)* 2013; **15**: 829-838 [PMID: 23458317 DOI: 10.1111/hpb.12038]

2 **O'Connell JB**, Maggard MA, Manunga J Jr, Tomlinson JS, Reber HA, Ko CY, Hines OJ. Survival after resection of ampullary carcinoma: a national population-based study. *Ann Surg Oncol* 2008; **15**: 1820-1827 [PMID: 18369675 DOI: 10.1245/s10434-008-9886-1]

3 **Cameron JL**, He J. Two thousand consecutive pancreaticoduodenectomies. *J Am Coll Surg* 2015; **220**: 530-536 [PMID: 25724606 DOI: 10.1016/j.jamcollsurg.2014.12.031]

4 **Chandrasegaram MD**, Chiam SC, Chen JW, Khalid A, Mittinty ML, Neo EL, Tan CP, Dolan PM, Brooke-Smith ME, Kanhere H, Worthley CS. Distribution and pathological features of pancreatic, ampullary, biliary and duodenal cancers resected with pancreaticoduodenectomy. *World J Surg Oncol* 2015; **13**: 85 [PMID: 25890023 DOI: 10.1186/s12957-015-0498-5]

5 **Sommerville CAM,** Limongelli P, Pai M. Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: An analysis of clinicopathological factors. *J Surg Oncol* 2009; **100**: 651-656 [PMID: 19722229 DOI: 10.1002/jso.21390]

6 **Morris-Stiff G**, Alabraba E, Tan YM, Shapey I, Bhati C, Tanniere P, Mayer D, Buckels J, Bramhall S, Mirza DF. Assessment of survival advantage in ampullary carcinoma in relation to tumour biology and morphology. *Eur J Surg Oncol* 2009; **35**: 746-750 [PMID: 19167859 DOI: 10.1016/j.ejso.2008.10.010]

7 **Okano K**, Oshima M, Yachida S, Kushida Y, Kato K, Kamada H, Wato M, Nishihira T, Fukuda Y, Maeba T, Inoue H, Masaki T, Suzuki Y. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma. *J Surg Oncol* 2014; **110**: 156-162 [PMID: 24619853 DOI: 10.1002/jso.23600]

8 **Zheng-Pywell R**, Reddy S. Ampullary Cancer. *Surg Clin North Am* 2019; **99**: 357-367 [PMID: 30846039 DOI: 10.1016/j.suc.2018.12.001]

9 **Kimura W,** Futakawa N, Yamagata S. Different Clinicopathologic Findings in Two Histologic Types of Carcinoma of Papilla of Vater. *Japanese J Cancer Res* 1994; **85**: 161-166 [DOI: 10.1111/j.1349-7006.1994.tb02077.x]

10 **Yoen H,** Kim JH, Hur BY, et al Prediction of tumor recurrence and poor survival of ampullary adenocarcinoma using preoperative clinical and CT findings. Eur Radiol. Published online 2020 [DOI: 10.1007/s00330-020-07316-4]

11 **Overman MJ**, Soifer HS, Schueneman AJ, Ensor J Jr, Adsay V, Saka B, Neishaboori N, Wolff RA, Wang H, Schnabel CA, Varadhachary G. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. *BMC Cancer* 2016; **16**: 668 [PMID: 27549176 DOI: 10.1186/s12885-016-2677-3]

12 **Schueneman A**, Goggins M, Ensor J, Saka B, Neishaboori N, Lee S, Maitra A, Varadhachary G, Rezaee N, Wolfgang C, Adsay V, Wang H, Overman MJ. Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma. *Br J Cancer* 2015; **113**: 64-68 [PMID: 25989273 DOI: 10.1038/bjc.2015.172]

13 **Shroff S**, Overman MJ, Rashid A, Shroff RT, Wang H, Chatterjee D, Katz MH, Lee JE, Wolff RA, Abbruzzese JL, Fleming JB, Wang H. The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. *Arch Pathol Lab Med* 2013; **137**: 1619-1626 [PMID: 24168499 DOI: 10.5858/arpa.2012-0418-OA]

14 **Kim BJ**, Jang HJ, Kim JH, Kim HS, Lee J. KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review. *Oncotarget* 2016; **7**: 58001-58006 [PMID: 27517148 DOI: 10.18632/oncotarget.11156]

15 **Valsangkar NP,** Ingkakul T, Correa-Gallego C, et al Survival in ampullary cancer: Potential role of different KRAS mutations. *Surg (United States)* 2015; **157**: 260-268 [DOI: 10.1016/j.surg.2014.08.092]

16 **Asano E**, Okano K, Oshima M, Kagawa S, Kushida Y, Munekage M, Hanazaki K, Watanabe J, Takada Y, Ikemoto T, Shimada M, Suzuki Y; Shikoku Consortium of Surgical Research (SCSR). Phenotypic characterization and clinical outcome in ampullary adenocarcinoma. *J Surg Oncol* 2016; **114**: 119-127 [PMID: 27132476 DOI: 10.1002/jso.24274]

17 **Park HM**, Park SJ, Han SS, Hong SK, Hong EK, Kim SW. Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer. *Medicine (Baltimore)* 2019; **98**: e17711 [PMID: 31689805 DOI: 10.1097/MD.0000000000017711]

18 **Lino-Silva LS**, Gómez-Álvarez MA, Salcedo-Hernández RA, Padilla-Rosciano AE, López-Basave HN. Prognostic importance of lymph node ratio after resection of ampullary carcinomas. *J Gastrointest Oncol* 2018; **9**: 1144-1149 [PMID: 30603134 DOI: 10.21037/jgo.2018.07.04]

19 **World Medical Association**. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 2013; **310**: 2191-2194 [PMID: 24141714 DOI: 10.1001/jama.2013.281053]

20 **Kimura W**, Futakawa N, Zhao B. Neoplastic diseases of the papilla of Vater. *J Hepatobiliary Pancreat Surg* 2004; **11**: 223-231 [PMID: 15368105 DOI: 10.1007/s00534-004-0894-7]

21 **Bowitz Lothe IM**, Kleive D, Pomianowska E, Cvancarova M, Kure E, Dueland S, Gladhaug IP, Labori KJ. Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy. *Pancreatology* 2019; **19**: 316-324 [PMID: 30713128 DOI: 10.1016/j.pan.2019.01.019]

22 **Lisita Rosa VD,** Maris Peria F, Ottoboni Brunaldi M. Carcinoma of Ampulla of Vater: Carcinogenesis and Immunophenotypic Evaluation. J Clin Epigenetics. 2017;03(03):1-5. DOI:10.21767/2472-1158.100059 [DOI:10.21767/2472-1158.100059]

23 **Zimmermann C**, Wolk S, Aust DE, Meier F, Saeger HD, Ehehalt F, Weitz J, Welsch T, Distler M. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. *Sci Rep* 2019; **9**: 12676 [PMID: 31481741 DOI: 10.1038/s41598-019-49179-w]

24 **Ang DC**, Shia J, Tang LH, Katabi N, Klimstra DS. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater. *Am J Surg Pathol* 2014; **38**: 1371-1379 [PMID: 24832159 DOI: 10.1097/PAS.0000000000000230]

25 **Liu F**, Shen D, Ma Y, Song Q, Wang H. Identification of ampullary carcinoma mixed subtype using a panel of six antibodies and its clinical significance. *J Surg Oncol* 2019; **119**: 295-302 [PMID: 30548547 DOI: 10.1002/jso.25311]

26 **Verbeke CS**, Menon KV. Redefining resection margin status in pancreatic cancer. *HPB (Oxford)* 2009; **11**: 282-289 [PMID: 19718354 DOI: 10.1111/j.1477-2574.2009.00055.x]

27 **Amini A**, Miura JT, Jayakrishnan TT, Johnston FM, Tsai S, Christians KK, Gamblin TC, Turaga KK. Is local resection adequate for T1 stage ampullary cancer? *HPB (Oxford)* 2015; **17**: 66-71 [PMID: 25395092 DOI: 10.1111/hpb.12297]

28 **Fernandez-Placencia R,** Berrospi-Espinoza F, Uribe-Rivera K, et al Preoperative Predictors for 90-Day Mortality after Pancreaticoduodenectomy in Patients with Adenocarcinoma of the Ampulla of Vater: A Single-Centre Retrospective Cohort Study. Sperti C, ed. *Surg Res Pract* 2021; **2021**: 1-9 [DOI: 10.1155/2021/6682935]

29 **Inoue Y**, Saiura A, Yoshioka R, Ono Y, Takahashi M, Arita J, Takahashi Y, Koga R. Pancreatoduodenectomy With Systematic Mesopancreas Dissection Using a Supracolic Anterior Artery-first Approach. *Ann Surg* 2015; **262**: 1092-1101 [PMID: 25587814 DOI: 10.1097/SLA.0000000000001065]

30 **Ecker BL**, McMillan MT, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Dickson EJ, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Javed AA, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, Poruk KE, Salem RR, Schmidt CR, Soares K, Stauffer JA, Valero V, Velu LKP, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr. Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy. *Ann Surg* 2018; **267**: 608-616 [PMID: 28594741 DOI: 10.1097/SLA.0000000000002327]

31 **Moekotte AL**, Malleo G, van Roessel S, Bonds M, Halimi A, Zarantonello L, Napoli N, Dreyer SB, Wellner UF, Bolm L, Mavroeidis VK, Robinson S, Khalil K, Ferraro D, Mortimer MC, Harris S, Al-Sarireh B, Fusai GK, Roberts KJ, Fontana M, White SA, Soonawalla Z, Jamieson NB, Boggi U, Alseidi A, Shablak A, Wilmink JW, Primrose JN, Salvia R, Bassi C, Besselink MG, Abu Hilal M. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. *Br J Surg* 2020; **107**: 1171-1182 [PMID: 32259295 DOI: 10.1002/bjs.11555]

32 **Zhou YM**, Liao S, Wei YZ, Wang SJ. Prognostic factors and benefits of adjuvant therapy for ampullary cancer following pancreatoduodenectomy: A systematic review and meta-analysis. *Asian J Surg* 2020; **43**: 1133-1141 [PMID: 32249101 DOI: 10.1016/j.asjsur.2020.03.007]

33 **Affi Koprowski M**, Sutton TL, Brinkerhoff BT, Grossberg A, Sheppard BC, Mayo SC. Oncologic outcomes in resected ampullary cancer: Relevance of histologic subtype and adjuvant chemotherapy. *Am J Surg* 2021; **221**: 1128-1134 [PMID: 33883071 DOI: 10.1016/j.amjsurg.2021.04.001]

34 **Quero G,** Fiorillo C, De Sio D, et al The role of mesopancreas excision for ampullary carcinomas: a single center propensity-score matched analysis. Hpb. Published online 2021 [DOI: 10.1016/j.hpb.2021.03.011]

35 **Neoptolemos JP**, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. *JAMA* 2012; **308**: 147-156 [PMID: 22782416 DOI: 10.1001/jama.2012.7352]

36 **Kim HS**, Jang JY, Yoon YS, Park SJ, Kwon W, Kim SW, Han HS, Han SS, Park JS, Yoon DS. Does adjuvant treatment improve prognosis after curative resection of ampulla of Vater carcinoma? A multicenter retrospective study. *J Hepatobiliary Pancreat Sci* 2020; **27**: 721-730 [PMID: 32652820 DOI: 10.1002/jhbp.801]

37 **Kamarajah SK**. Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis. *Clin Transl Oncol* 2018; **20**: 1212-1218 [PMID: 29497964 DOI: 10.1007/s12094-018-1849-9]

38 **Ecker BL**, Vollmer CM Jr, Behrman SW, Allegrini V, Aversa J, Ball CG, Barrows CE, Berger AC, Cagigas MN, Christein JD, Dixon E, Fisher WE, Freedman-Weiss M, Guzman-Pruneda F, Hollis RH, House MG, Kent TS, Kowalsky SJ, Malleo G, Salem RR, Salvia R, Schmidt CR, Seykora TF, Zheng R, Zureikat AH, Dickson PV. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma. *JAMA Surg* 2019; **154**: 706-714 [PMID: 31141112 DOI: 10.1001/jamasurg.2019.1170]

39 **Narang AK,** Miller RC, Hsu CC. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic collaborative study. *Radiat Oncol* 2011; **6**: 126 [DOI: 10.1186/1748-717x-6-126]

40 **Regalla DKR**, Jacob R, Manne A, Paluri RK. Therapeutic options for ampullary carcinomas. A review. *Oncol Rev* 2019; **13**: 440 [PMID: 31565197 DOI: 10.4081/oncol.2019.440]

41 **Bonet M**, Rodrigo A, Vázquez S, Carrizo V, Vilardell F, Mira M. Adjuvant therapy for true ampullary cancer: a systematic review. *Clin Transl Oncol* 2020; **22**: 1407-1413 [PMID: 31927720 DOI: 10.1007/s12094-019-02278-6]

42 **Miura JT**, Jayakrishnan TT, Amini A, Johnston FM, Tsai S, Erickson B, Quebbeman EJ, Christians KK, Evans DB, Gamblin TC, Turaga KK. Defining the role of adjuvant external beam radiotherapy on resected adenocarcinoma of the ampulla of vater. *J Gastrointest Surg* 2014; **18**: 2003-2008 [PMID: 25159502 DOI: 10.1007/s11605-014-2629-7]

43 **Vo NP,** Nguyen HS, Loh EW, Tam KW. Efficacy and safety of adjuvant therapy after curative surgery for ampullary carcinoma: A systematic review and meta-analysis. *Surg (United States)* 2021: 1-10 [DOI: 10.1016/j.surg.2021.03.046]

44 **Kondo S**, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Furuse J, Saito H, Tsuyuguchi T, Yamamoto M, Kayahara M, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Hirano S, Amano H, Miura F; Japanese Association of Biliary Surgery; Japanese Society of Hepato-Biliary-Pancreatic Surgery; Japan Society of Clinical Oncology. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. *J Hepatobiliary Pancreat Surg* 2008; **15**: 41-54 [PMID: 18274843 DOI: 10.1007/s00534-007-1279-5]

45 **Mafficini A**, Amato E, Cataldo I, Rusev BC, Bertoncello L, Corbo V, Simbolo M, Luchini C, Fassan M, Cantù C, Salvia R, Marchegiani G, Tortora G, Lawlor RT, Bassi C, Scarpa A. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. *Ann Surg* 2018; **267**: 149-156 [PMID: 27611608 DOI: 10.1097/SLA.0000000000001999]

46 **Chavez MT**, Sharpe JP, O'Brien T, Patton KT, Portnoy DC, VanderWalde NA, Deneve JL, Shibata D, Behrman SW, Dickson PV. Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma. *Am J Surg* 2017; **214**: 856-861 [PMID: 28285709 DOI: 10.1016/j.amjsurg.2017.01.029]

**Footnotes**

**Institutional review board statement:** Our institutional review board approved this study (Protocol Number 21-17), according to the Declaration of Helsinki19.

**Informed consent statement:** Informed consent was waived by the IRB (IRB No. 21-17).

**Conflict-of-interest statement:** No conflicts of interest to be declared.

**Data sharing statement:** According to the institutional policy, no data from our patients would be shared.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 10, 2021

**First decision:** August 9, 2021

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Peru

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Andrejic-Visnjic B, Mirshahi M, Yamada T **S-Editor:** Wu YXJ **L-Editor:** A **P-Editor:** Wu YXJ

**Figure Legends**



**Figure 1 Survival probability of patients with adenocarcinoma of the ampulla of Vater undergoing pancreaticoduodenectomy.**



**Figure 2 Comparison of survival probability between the intestinal/other (A) and pancreaticobiliary (B) types in patients with pT3 and pN+ adenocarcinoma of the ampulla of Vater.**

**Table 1 Clinical, laboratory and operative patient characteristics (*n* = 83)**

|  |
| --- |
| **Clinical, laboratory and operative patient characteristics (*n* = 83)** |
| Age (yr), median (IQR) | 59 (49–67) |
| Sex, male/female, *n* (%) | 36 (43)/47 (57) |
| Perioperative transfusion, *n* (%) | 21 (25) |
| Haemoglobin in g/L, median (IQR) | 115 (108–127) |
| Platelet count in 109/L, median (IQR) | 285 (243–372) |
| International Normalized Ratio, median (IQR) | 1.06 (1.01–1.15) |
| Serum glucose in mmol/L, median (IQR) | 5.1 (4.8–5.7) |
| Serum creatinine in mmol/L, median (IQR) | 53 (47–65) |
| Serum albumin in g/L, median (IQR) | 38.1 (32–41.1) |
| Serum total bilirubin in µmol/L, median (IQR) | 23.9 (12.9–60) |
| Serum CA 19-9 in IU/mL, median (IQR) | 26.3 (10–91.4) |
| Pancreaticoduodenectomy |  |
| Pylorus-preserving PD, *n* (%) | 69 (83) |
| Whipple procedure, *n* (%) | 14 (17) |

IQR: Interquartile range; PD: Pancreaticoduodenectomy.

**Table 2 Histopathologic characteristics (*n* = 83)**

|  |
| --- |
| **Histopathologic characteristics (*n* = 83)** |
| Tumour size in mm, median (IQR) | 27 (17–40) |
| Subtype, *n* (%) |  |
| Intestinal | 57 (69) |
| Pancreatobiliary | 19 (23) |
| Others | 7 (8) |
| Tumour status, *n* (%) |  |
| T1 | 7 (8) |
| T2 | 44 (53) |
| T3 | 32 (39) |
| Number of lymph nodes assessed, median (IQR) | 17 (12–24) |
| Lymph node status, *n* (%) |  |
| N0 | 50 (60) |
| N1 | 22 (26) |
| N2 | 11 (14) |
| Differentiation, *n* (%) |  |
| Well differentiated | 25 (30) |
| Moderately differentiated | 53 (64) |
| Poorly differentiated | 5 (6) |
| Lymphovascular invasion | 30 (36) |
| Perineural invasion | 26 (31) |

IQR: Interquartile range.

**Table 3 Recurrence patterns after pancreaticoduodenectomy (*n* = 19)**

|  |  |
| --- | --- |
| **Organs involved** |  |
| **Distant metastasis, *n* (%)** | **(A) First organ** | **(B) Second organ** | **(C) Third organ** | **A + B + C** | **%** |
| Liver | 8 | 3 | 1 | 12 | 32 |
| Peritoneum | 4 | 3 | 1 | 8 | 22 |
| Lung | 4 | 2 | 1 | 7 | 19 |
| Supraclavicular lymph node | 1 |  |  | 1 | 3 |
| Bone |  | 1 |  | 1 | 3 |
| Suprarenal gland |  |  | 1 | 1 | 3 |
| Sub-table total |  |  |  | 30 | 81 |
| Lymph nodal recurrence, *n* (%) |  |  |  |  |  |
| Celiac trunk |  | 1 |  | 1 | 3 |
| Hepatic hilum |  | 1 |  | 1 | 3 |
| Mesenteric lymph nodes | 1 | 1 |  | 2 | 5 |
| Retroperitoneal lymph nodes | 2 | 1 |  | 3 | 8 |
| Sub-table total |  |  |  | 7 | 19 |
| Total |  |  |  | 37 | 100 |

**Table 4 Cox regression model analysis for predictors of overall survival**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **Hazard ratio** | **95%CI** | ***P* value** |
| **Lower** | **Upper** |
| Age in yr |  |  | 0.355 |
| Tumour size in mm | 1.03 | 1 | 1.06 | 0.059 |
| Histopathologic subtype |  |  |
| Intestinal/other types |  |  |  |
| Pancreatobiliary type | 2.7 | 1.2 | 6.2 | 0.025 |
| T classification |  |  |  |
| T1-T2 |  |  |  |
| T3 | 6.4 | 2.5 | 16.3 | < 0.001 |
| Lymph node metastasis |  |  |
| No |  |  |  |
| Yes | 4.5 | 1.8 | 11.3 | 0.001 |
| Differentiation grade |  | 0.54 |
| Well differentiated |  |  |
| Moderately differentiated |  | 0.268 |
| Poorly differentiated |  | 0.755 |
| Perineural invasion |  | 0.517 |
| Lymphovascular invasion |  | 0.26 |

CI: Confidence interval.